EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
12
06
2020
accepted:
13
08
2020
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
Substances chimiques
Ustekinumab
FU77B4U5Z0
Adalimumab
FYS6T7F842
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2461-2498Subventions
Organisme : Medical Research Council
ID : MR/T02383X/1
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions, Vol. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration. 2011.
Augustin M, Alvaro-Gracia JM, Bagot M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26(Suppl 4): 1-16.
Campanati A, Ganzetti G, Giuliodori K, Molinelli E, Offidani A. Biologic therapy in psoriasis: safety profile. Curr Drug Safety 2016; 11: 4-11.
International Federation of Psoriasis Association. Position Statement of biosimilars - IFPA. 2019; p. 2.
International Federation of Psoriasis Association. IFPA Advocacy Toolkit for UNIVERSAL HEALTH COVERAGE. 2019.
Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736.
Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685-704.
Löfvendahl S. Burden of Disease in Psoriasis and Psoriatic Arthritis. Occurrence, Healthcare Use, Costs and Health Outcome. Lund: Lund University; Occurrence, Healthcare Use, Costs and Health Outcome. 2016. https://lup.lub.lu.se/search/publication/8069fa54-3e25-4411-8717-c1e40a0f7026
Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147(Suppl 62): 50.
Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007; 156: 945-950.
Strober B, Ryan C, van de Kerkhof P et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020; 82: 117-122.
Dauden E, Puig L, Ferrandiz C, Sanchez-Carazo JL, Hernanz-Hermosa JM. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2016; 30(Suppl 2): 1-18.
Nast A, Gisondi P, Ormerod AD et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277-2294.
Nast A, Spuls PI, van der Kraaij G et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017; 31: 1951-1963.
Mrowietz U, de Jong EM, Kragballe K et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 438-453.
Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas dermo-sifiliograficas 2015; 106: 155-157.
Mahil SK, Wilson N, Dand N et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166.
Seston EM, Ashcroft DM, Griffiths CEM. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007; 143: 1175-1179.
Egeberg A, Andersen YMF, Halling-Overgaard AS et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol 2020; 34: 39-46.
Nast A, Sporbeck B, Rosumeck S et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013; 133: 1963-1970.
Pham PA, Dressler C, Eisert L, Nast A, Werner RN. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Rheumatol Int 2019; 39: 605-618.
Nast A, Dilleen M, Liyanage W, Aikman L, Szczypa P, Dressler C. Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. Br J Dermatol 2018; 178: 400-405.
Zidane M, Dressler C, Gaskins M, Nast A. Decision-analytic modeling for time-effectiveness of the sequence of induction treatments for moderate to severe plaque psoriasis. JAMA Dermatol 2019; 155: 1380.
Guyatt G, Oxman AD, Akl EA et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-394.
Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-382.
The GRADE Working Group. Vol. 2018. 2018.
Werner RN, Nikkels AF, Marinovic B et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol 2017; 31: 9-19.
Werner RN, Nikkels AF, Marinovic B et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol 2017; 31: 20-29.
Sbidian E, Chaimani A, Afach S et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database System Rev 2020; 1: Cd011535.
Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 1-70.
Gisondi P, Altomare G, Ayala F et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 774-790.
Kragballe K, Jansen CT, Geiger JM et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta dermato-venereologica 1989; 69: 35-40.
Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ 2012; 345: e6712.
van der Kraaij GE, Balak DMW, Busard CI et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180: 31-42.
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33: 464-483.
Carretero G, Ribera M, Belinchon I et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas dermo-sifiliograficas 2013; 104: 598-616.
Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
Mrowietz U, Morrison PJ, Suhrkamp I, Kumanova M, Clement B. The pharmacokinetics of fumaric acid esters reveal their in vivo effects. Trends Pharmacol Sci 2018; 39: 1-12.
Malaviya AN. Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen. Clin Rheumatol 2017; 36: 279-285.
Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466-469.
Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database System Rev 2000: CD000951.
van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatism 2001; 44: 1515-1524.
Haque Hussain SS, Wallace M, Belham M et al. Infective endocarditis complicating adalimumab therapy for psoriasis. Clin Exp Dermatol 2014; 39: 555-556.
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals Rheum Dis 2013; 72: 517-524.
Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Therapeut Clin Risk Manage 2008; 4: 345-351.
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Therapeut 2008; 117: 244-279.
Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008; 66: 618-625.
Esposito M, Giunta A, Mazzotta A et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012; 225: 312-319.
Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheumatism 2008; 59: 996-1001.
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009; 20: 100-108.
Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 2018; 57: 1521-1532.
Pappas DA, Giles JT. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections? Curr Opin Rheumatol 2008; 20: 450-456.
den Broeder AA, Creemers MC, Fransen J et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34: 689-695.
Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI. Combined use of systemic agents for psoriasis: a systematic review. JAMA Dermatol 2014; 150: 1213-1220.
Davila-Seijo P, Dauden E, Descalzo MA et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol 2017; 137: 313-321.
European Medicines Agency. Humira [Humira: EPAR - Product Information]. 2014.
European Medicines Agency. Otezla - Summary of product characteristics (Annex I). 08/07/2016 Otezla -EMEA/H/C/003746 -PSUSA/10338/201506. 2016.
Papp K, Cather JC, Rosoph L et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738-746.
Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49.
Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387-1399.
Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013; 27: e376-e383.
Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. Br J Clin Pharmacol 2014; 78: 1050-1057.
Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol 2019; 82: 352-359.
Lebwohl MG, Blauvelt A, Menter A et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with Brodalumab for 5 years in a long-term, open-label, Phase II study. Am J Clin Dermatol 2019; 20: 863-871.
Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis. New England J Med 2015; 373: 1318-1328.
Lebwohl MG, Papp KA, Marangell LB et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol 2018; 78: 81-89.e5.
European Medicines Agency. Summary of product characteristics Brodalumab.
Hashim PW, Chen T, Lebwohl MG, Marangell LB, Kircik LH. What lies beneath the face value of a BOX WARNING: A deeper look at Brodalumab. J Drugs Dermatol 2018; 17: s29-s34.
Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 2017; 177: 47-62.
Pappas PG, Kauffman CA, Andes DR et al. Clinical Practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016; 62: e1-50.
Lortholary O, Petrikkos G, Akova M et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18(Suppl 7): 68-77.
Gottlieb AB, Blauvelt A, Thaci D et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018; 79: 302-314.e6.
Lebwohl M, Blauvelt A, Paul C et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol 2018; 79: 266-276.e5.
Wang X, Liu Q, Wu L, Nie Z, Mei Z. Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis. J Cancer 2020; 11: 1047-1055.
Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
Papp KA, Poulin Y, Bissonnette R et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66: e33-e45.
Wyeth Europa Ltd. Fachinformation Enbrel 50 mg Fertigspritze. In. Taplow, Maidenhead. 2007.
European Medicines Agency. Taltz [Taltz: EPAR - Product Information].
European Medicines Agency. Summary of product characteristics Ixekizumab. 2019.
Menter A, Warren RB, Langley RG et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol 2017; 31: 1686-1692.
Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol 2017; 77: 855-862.
Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol 2019; 34: 301-309.
Papp K, Maari C, Cauthen A et al. An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA>1 at week 12. Br J Dermatol 2019; 183: 52-59.
European Medicines Agency. Skyrizi - EMEA/H/C/004759 - IA/0006. 2019.
Khatri A, Cheng L, Camez A, Ignatenko S, Pang Y, Othman AA. Lack of effect of 12-week treatment with risankizumab on the pharmacokinetics of cytochrome P450 probe substrates in patients with moderate to severe chronic plaque psoriasis. Clin Pharmacokinet 2019; 58: 805-814.
European Medicines Agency. Cosentyx - Summary of product characteristics (Annex I). 01/04/2016 Cosentyx -EMEA/H/C/003729 -II/0008. 2016.
Deodhar A, Mease PJ, McInnes IB et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Therapy 2019; 21: 111.
Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693-1700.
Novartis Pharmaceuticals Corporation. Secukinumab (AIN457) - ADVISORY COMMITTEE BRIEFING MATERIAL: AVAILABLE FOR PUBLIC RELEASE In. U.S. Food and Drug Administration. 2014.
Swiss Specialist Information Ilumetri. 2018.
Reich K, Warren RB, Iversen L et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. The British journal of dermatology 2019;182:605-617.
European Medicines Agency. IlumetriTM (Tildrakizumab) Summary of product characteristics. 2019.
Cerrone M, Wang X, Neary M et al. Pharmacokinetics of Efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin Infect Dis 2019; 68: 446-452.
European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012.
Gerdes S, Thaci D, Griffiths CEM et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol 2018; 32: 420-427.